EU and US could reach trade deal this weekend - Reuters
In a recent transaction disclosed by Avita Medical (TASE:BLWV), Inc. (NASDAQ:RCEL), Robert McNamara, a director at the company, acquired 10,000 shares of common stock. The purchase, which took place on February 20, 2025, was executed at a weighted average price of $10.09 per share, resulting in a total transaction value of approximately $100,900. The timing appears opportune, as InvestingPro analysis indicates the stock is currently undervalued, with shares showing strong momentum, gaining over 16% in the past week.
The shares were acquired at prices ranging from $9.89 to $10.19. Following this transaction, McNamara holds 45,749 shares in the company, which includes unvested restricted stock units (RSUs). The stock has demonstrated significant volatility, trading between $7.51 and $18.93 over the past 52 weeks.
Avita Medical, based in Valencia, California, focuses on the development and commercialization of innovative medical devices. The company is known for its work in the field of regenerative medicine, particularly in the treatment of skin injuries and defects. With impressive revenue growth of 28% and a robust gross profit margin of 86%, the company shows promising fundamentals. For deeper insights into Avita Medical’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
In other recent news, Avita Medical Ltd . has reported a commercial revenue of $18.4 million, marking a 29% increase year-over-year, although it fell short of analyst expectations. Despite this shortfall, Avita reiterated its fiscal year 2025 revenue forecast, projecting it to be between $100 million and $106 million, with anticipated growth from new product launches like RECELL GO Mini. The company recently received FDA approval for the RECELL GO Mini, a device aimed at treating smaller wounds, which is expected to enhance its market presence in trauma and burn centers. Analysts at Cantor Fitzgerald have maintained an Overweight rating on Avita, reflecting confidence in the company’s growth prospects. Meanwhile, Lake Street Capital Markets adjusted Avita’s price target to $14, retaining a Buy rating, and noted the significance of recent FDA approvals for future revenue growth. D. Boral (OTC:BOALY) Capital has initiated coverage with a Buy rating and a $25 price target, citing Avita’s strong U.S. market penetration and innovative tissue regeneration technology. The focus on expanding the product portfolio and market reach positions Avita for potential growth in the coming year. These developments highlight Avita Medical’s strategic efforts in advancing its skin regeneration products and expanding its market footprint.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.